Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AIDS-associated malignant lymphoma.

A M Levine1

  • 1University of Southern California School of Medicine, Los Angeles.

The Medical Clinics of North America
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

This study examines lymphoma in immune dysfunction, noting high-grade B-cell lymphomas with extranodal spread, similar to HIV-associated cases. Treatment intensity should be tailored to prognostic factors for better outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lactobacillus johnsonii supplementation attenuates respiratory viral infection via metabolic reprogramming and immune cell modulation.

Mucosal immunology·2017
Same author

The Medical Bookshelf.

Postgraduate medicine·2016
Same author

Problems+Solutions.

Postgraduate medicine·2016
Same author

Avulsion of the transverse ligament associated with a fracture of the atlas: a case report.

Orthopedics·2014
Same author

Transmission x-ray diffraction grating alignment using a photoelastic modulator.

Applied optics·2010
Same author

Multiple scattering of laser light from a turbid medium.

Applied optics·2010
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Lymphoma manifests similarly across various immune dysfunction states, including congenital, acquired, and iatrogenic.
  • Clinical and pathological features in these conditions mirror those observed in patients with human immunodeficiency virus (HIV)-induced immunodeficiency.

Purpose of the Study:

  • To characterize high-grade B-cell lymphomas in immune dysfunction.
  • To identify prognostic factors influencing survival in these patients.
  • To guide chemotherapy intensity based on patient indicators.

Main Methods:

  • Review of clinical and pathological data for lymphoma patients with immune dysfunction.
  • Analysis of presenting disease characteristics, including extranodal and central nervous system (CNS) involvement.

Related Experiment Videos

  • Evaluation of prognostic factors such as performance status, AIDS history, disease stage, and CD4 cell counts.

    • Main Results:

    • High-grade B-cell lymphomas are common, often presenting with widespread extranodal disease.
    • Unusual disease sites, including the CNS, may be observed.
    • Predictive factors for short survival include low performance status, prior AIDS diagnosis, advanced stage, bone marrow involvement, and low CD4 counts.

    Conclusions:

    • Chemotherapy in immune-compromised lymphoma patients requires careful consideration of potential opportunistic infections.
    • Less intensive chemotherapy regimens may be suitable for patients with poor prognostic indicators.
    • Patients without poor prognostic factors may tolerate and benefit from dose-intensive chemotherapy.